The global diabetes therapeutics market is estimated to grow at a high CAGR in the forecasting period (2022-2029).
Growing focus on regenerative therapies, the presence of a strong product pipeline portfolio, companies focus on oral insulin therapies, and increasing technological advancements across the world which are helping in R&D are some of the key trends in the global diabetes therapeutics market.
Consumer’s preference for self-medication for the treatment of diabetes, growing demand for biologics, the presence of high unmet needs, and broad scope for Dimethyl disulfide (DMD’s) are some of the key factors driving the growth of the diabetes therapeutics market.
Growing complexity in storage and distribution of the insulin, the highly unpredictable nature of drugs in the outcome on humans, raising concerns in the scientific communities, and the gap in the national level diabetes management plans are some of the critical challenges for the growth of the diabetes therapeutics market.
The diabetes therapeutics market by disease type has been segmented into type 1 diabetes, type 2 diabetes, and Gestational diabetes. Type 2 diabetes is one of the most prevalent forms of diabetes across the world.
The majority of the population suffering from diabetes is the older population, though it is estimated the market is growing at a higher rate in younger people. With marketed products, Actos, Januvia, Lantus, and Lantus Solostar have the highest revenue share in the United States. The gestational diabetes market is growing at the highest growth rate in the forecasted period.
North America dominates the global diabetes therapeutics market share in 2017, and the region is estimated to dominate the global market by the end of the forecasted period of 2026.
The growing prevalence of diabetes in the United States and potential opportunities for the development of the high unmet needs, increasing demand for a safer and efficient drug are the significant factors for the market to dominate by the end of the forecasted period. The prevalence of type II diabetes in Europe is increasing due to changing lifestyles and changing food consumption preferences.
The global diabetes therapeutics market is a consolidated market with 90% of the market being dominated by the top 10 companies in the industry. Novo Nordisk, Sanofi, Eli Lilly, and Merck are some of the major companies in the diabetes therapeutics industry with these four companies occupying more than 70% of the market share in 2017.
Merck is estimated to significantly lose it’s more than half of the market share by the end of the forecasted period 2025 with Boehringer Ingelheim gaining a large market share. Novo Nordisk, Eli Lilly, Boehringer Ingelheim, and Sanofi have the largest market share in 2026 with these four companies occupying 72.6% market share.
Segmentation by Marketed Drugs
Humalog (Eli Lilly)
Victoza (Novo Nordisk)
Trulicity (Eli Lilly)
Levemir (Novo Nordisk)
Trajenta (Boehringer Ingelheim)
Novolog (Novo Nordisk)
Segmentation by Diseases
Type 1 diabetes
Type 2 diabetes
Segmentation by Drug Class
The report also covers the key factors impacting the market, Porter 5 Forces, Market Share Analysis, Price trend analysis, Product Benchmarking, and company profiles.
Get your free sample proposal with a single click!